- Home
- VLGEA vs LXRX Comparison
VLGEA vs LXRX Comparison
Compare VLGEA & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VLGEA | LXRX |
|---|---|---|
| Founded | 1937 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 480.8M | 541.5M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | VLGEA | LXRX |
|---|---|---|
| Price | $35.08 | $1.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.23 |
| AVG Volume (30 Days) | 41.2K | ★ 2.0M |
| Earning Date | 12-02-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | ★ 4.59 | N/A |
| EPS | ★ 3.75 | N/A |
| Revenue | ★ $2,345,586,000.00 | $70,864,000.00 |
| Revenue This Year | N/A | $56.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | 3.88 | ★ 1255.21 |
| 52 Week Low | $29.64 | $0.28 |
| 52 Week High | $40.15 | $1.66 |
Technical Indicators
Market Signals| Indicator | VLGEA | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 49.99 |
| Support Level | $34.26 | $1.34 |
| Resistance Level | $36.05 | $1.47 |
| Average True Range (ATR) | 0.86 | 0.07 |
| MACD | 0.13 | -0.00 |
| Stochastic Oscillator | 48.09 | 50.00 |
Price Performance
Historical ComparisonAbout VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.